Combining immune checkpoint inhibitors with standard treatment regimens in advanced human epidermal growth factor receptor-2 positive gastric cancer patients

Table 4 Comparison of grade 3-4 adverse reactions, n (%)

Adverse reaction	Control (n = 54)	Observation (n = 50)	χ2	P value
Leukopenia	5 (9.26)	2 (4.00)	0.459	0.497
Neutropenia	9 (16.67)	2 (4.00)	4.404	0.035
Lymphopenia	7 (12.96)	6 (12.00)	0.022	0.882
Thrombocytopenia	9 (16.67)	10 (20.00)	0.193	0.660
Hemoglobin reduction	4 (7.41)	2 (4.00)	0.104	0.746
Gastrointestinal reaction	2 (3.70)	0 (0.00)	0.000	1.000
Abnormal liver function	0 (0.00)	2 (4.00)	0.000	1.000
Pneumonia	0 (0.00)	1 (2.00)	0.000	1.000
Hypothyroidism	0 (0.00)	0 (0.00)	0.000	1.000